New Drugs in the Pipeline for the Treatment of HIV: a Review

Purpose of Review The purpose of this paper is to review therapies with new mechanisms of action for the treatment of HIV that are at least in phase 2 clinical trials. Recent Findings There are several new mechanisms of action being represented within clinical development, including histone deacetyl...

Full description

Saved in:
Bibliographic Details
Published in:Current infectious disease reports 2017-11, Vol.19 (11), p.42-42, Article 42
Main Authors: Gravatt, Leigh Anne Hylton, Leibrand, Crystal R, Patel, Sulay, McRae, MaryPeace
Format: Article
Language:English
Subjects:
Antibodies
Antimicrobial Development and Drug Resistance (A Pakyz
Antiretroviral agents
Antiretroviral drugs
Chemokines
Clinical trials
Drug dosages
Drug resistance
Drug therapy
FDA approval
Gene expression
HIV
Human immunodeficiency virus
Infections
Infectious Diseases
Medicine
Medicine & Public Health
Patients
Pharmaceutical sciences
Pharmacy
Plasma
Section Editor
Topical Collection on Antimicrobial Development and Drug Resistance
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review The purpose of this paper is to review therapies with new mechanisms of action for the treatment of HIV that are at least in phase 2 clinical trials. Recent Findings There are several new mechanisms of action being represented within clinical development, including histone deacetylase (HDAC) inhibitors, gene therapies, broadly neutralizing anti-HIV antibodies, immune modulation, and drugs with new mechanisms to block HIV entry. The new therapies are being developed for both as add-on therapy to existing combination antiretroviral therapy and as agents to be used during treatment interruption. The current drugs in development have had varying degrees of success in the early trials. Summary Each of these new drugs may potentially fill a void in current antiretroviral therapy (ART) therapies, which will ultimately lead to improved outcomes in HIV-infected individuals.
ISSN:1523-3847
1534-3146
DOI:10.1007/s11908-017-0601-x